"This course helped me to realise that I want to serve as a bridge between patients and researchers." 🔵 This is Katell's story: part of our cancer patient advocate voices series. 🔗 Learn more about our VOICE Science for Patient Advocates course: https://lnkd.in/e_2HgQvF 💬 "My name is Katell Maguet, I’m from France, and I’m currently based in The Netherlands. I’m a patient advocate for Cancer Grand Challenges’ team eDyNAmiC, which aims to understand how small circular DNA particles, called ecDNA, enable tumours to evolve and evade treatment. Three and a half years ago, I was diagnosed with stage 3 colorectal cancer at 40. I had multiple rounds of surgery and faced significant complications. I became aware of how little awareness there is of early-onset colorectal cancer, so I began sharing my story on LinkedIn. That’s where I first saw David (Dave) Chuter (who organises the VOICE course) posting about eDyNAmiC, which led me to become involved with the Cancer Grand Challenges and eventually with VOICE. I have a scientific background, having studied food science at university, which involved a lot of biology and chemistry. After university, I shifted my focus to consumer research, but I remember doing PCR reactions years ago, so it was fascinating coming back to the lab during VOICE. The chemistry between the VOICE participants was fantastic. We stayed at the university, ate together and got to know one another. Spending time with people who have different types of cancer gave me a fresh perspective. I know a lot about colorectal cancer but not as much about other types. The course made me realise that we shouldn’t even be talking about cancer by the organ it affects but by the type of tumour and the biomarkers. Every cancer is different, and there are even significant differences within the same tumour. I was shocked to learn that the chemotherapy I received was discovered in the 1960s – it’s 60 years old and still in use. Those older treatments can be brutal and have many side effects. But the new drugs are unbelievable. To meet the researchers working on them was inspiring. This course helped me to realise that I want to serve as a bridge between patients and researchers. I want to be a scientific patient voice and help fight fake news. Not every patient has the chance to come and take a course like VOICE, so I’m eager to share what I have learned. I’m also excited to work with the course organisers on the impact of VOICE. I’m incredibly grateful to all the researchers for their time and passion throughout the week." Queen Mary University of London | Queen Mary Faculty of Medicine and Dentistry | Cancer Research UK City of London Centre | #colorectalcancer #cancerpatient #patientadvocate
Barts Cancer Institute (Queen Mary University of London)
Research Services
A leading UK cancer research institute at Queen Mary University of London and a Cancer Research UK Centre of Excellence.
About us
Barts Cancer Institute (BCI) at Queen Mary University of London, is a leading UK cancer research institute, and key partner in the Cancer Research UK City of London Centre. Under the leadership of the Director, Professor Nitzan Rosenfeld, and supported by an Executive Board of senior investigators, we have created an academic environment fitting for an internationally recognised, comprehensive cancer centre. BCI, as part of the Barts and The London School of Medicine and Dentistry, is in the top 10 multi-faculty research institutions (REF 2014). Our staff and students focus their efforts on two objectives; how to increase the chances of survival through early detection and diagnosis; and improving patient survival through the discovery and development of more effective and innovative therapies. These objectives are underpinned by research into improving our understanding of the basic cell and molecular biology of cancer and the body’s natural immune response to it. We also use our expertise to teach and educate students and professionals about the science of and gold-standard clinical approaches to cancer, and to engage our local population. We hope to make the often difficult subject of cancer accessible to anyone that requires or is interested in our research.
- Website
-
https://www.bartscancer.london
External link for Barts Cancer Institute (Queen Mary University of London)
- Industry
- Research Services
- Company size
- 201-500 employees
- Headquarters
- London
- Type
- Nonprofit
- Founded
- 2003
- Specialties
- Cancer research, Translational research, and Clinical research
Locations
-
Primary
Barts and The London School of Medicine and Dentistry
Queen Mary University of London, Charterhouse Square
London, EC1M 6BQ, GB
Employees at Barts Cancer Institute (Queen Mary University of London)
Updates
-
Congratulations to our BCI long-service award recipients! 🏆 We had a fantastic afternoon on Friday celebrating staff who have been at the institute for 5, 10, 15 (left) and even 20 years (right). In total, we recognised 49 staff members for their continued dedication to supporting life-changing cancer research – whether as an academic, clinician, technician or professional service staff. Thank you to everyone who joined us! Queen Mary University of London | Queen Mary Faculty of Medicine and Dentistry | Cancer Research UK City of London Centre | #staffrecognition #awards
-
⏳ Time is running out to register for our Scientific Basis of Urology Course. Join us for a four-day executive course taught by distinguished expert faculty, including key opinion leaders in their fields. We will explore the basic science of benign and malignant urological conditions. 🔗Find out more and register: https://lnkd.in/eZafXWdU 📆 Monday 9th – Thursday 12th December 2024 📍 In person in London, UK, or online. Please share with colleagues in your network who may be interested. This course is CPD accredited by THE BRITISH ASSOCIATION OF UROLOGICAL SURGEONS LIMITED and is ideal preparation for FRCS(Urol), FEBU and other postgraduate exams. #urology #cpd #surgery #postgraduate #executivecourse #studywithus
-
Barts Cancer Institute (Queen Mary University of London) reposted this
Queen Mary is part of a nationwide team of universities, hospitals and industry, launching a multi-million-pound UK-wide platform to understand #immunotherapy response and side effects in #cancer. Led by the The Francis Crick Institute and The Royal Marsden NHS Foundation Trust, the MANIFEST programme (Multiomic Analysis of Immunotherapy Features Evidencing Success and Toxicity), has been set up to evaluate the many barriers to the success of treatments based on using drugs to help the immune system fight cancer. This immunotherapy approach is a frontline treatment for some types of cancer like melanoma (a form of skin cancer), and long-term studies have shown that it can completely eradicate advanced disease for some patients. However, the majority of people with cancer do not benefit, with many relapsing or experiencing significant side effects. Even in melanoma, where immunotherapy is most successful, only 50% respond. MANIFEST will aim to validate biomarkers - signs that suggest to doctors whether someone will or will not benefit from a given drug – and identify which are present in patients before they start immunotherapy, and to develop tests that can monitor them during treatment. The initial testing will include 3000 patients who have already completed their treatment and then 3000 who are starting treatment across the UK for breast, bladder, kidney and skin cancer, with plans to include additional cancer types as the programme expands. Over four years, data will be collected from these patients, using procedures like blood tests, stool samples and tissue biopsies. The team will analyse different aspects of cancerous tumours, including their genetic makeup, where they are in relation to immune cells, and what chemical signals they are producing. They will also generate a profile of immune cells in each patient’s bloodstream and analyse their gut microbiome. Prof Kairbaan Hodivala-Dilke, Deputy Director Barts Cancer Institute (Queen Mary University of London), said: “We are very proud to be part of this exciting MRC MANIFEST UK consortium led by the The Francis Crick Institute. MRC MANIFEST leverages £9m from the Medical Research Council and the Office for Life Sciences, and £12.9m in matched funds from industry partners, this programme will involve thousands of patients treated with immunotherapy from across the UK. Integrating Queen Mary-initiated spatial omics analysis and forces from Tom Powels and Bernadette Szabados in bladder cancer, MANIFEST will discover and develop new biomarkers to optimise the use of the immunotherapies across multiple cancer types.”
-
We're pleased to play a part in this exciting UK-wide collaboration seeking to address a critical challenge in cancer treatment: predicting how patients will respond to immunotherapy. Queen Mary University of London is one of 16 academic partners contributing to the project. Professor Tom Powles, Professor Kairbaan Hodivala-Dilke and Dr Bernadett Szabados will lead Queen Mary's contribution, bringing together expertise in mapping out the locations and involvement of immune cells in different types of cancer. Find out more about MANIFEST: https://lnkd.in/gvR9sZXv
We’re delighted to be leading a new project alongside The Royal Marsden NHS Foundation Trust to study responses to cancer immunotherapy. The platform has already received more than £20 million in public and industry investment and will involve thousands of people from across the UK receiving immunotherapy. Find out more about the platform, and hear from Crick and Royal Marsden group leader and consultant oncologist SAMRA TURAJLIC, science and technology secretary Peter Kyle, and Alex Green, who received immunotherapy treatment for melanoma ➡️ https://lnkd.in/ewvkJ-Fq
-
Barts Cancer Institute (Queen Mary University of London) reposted this
Group Leader Barts Cancer Institute, Queen Mary University of London presso Barts and the London School of Medicine and Dentistry
We have a novel PhD project available within the CRUK City of London network to identify novel mechanisms of sensitization to PARP inhibitors. If you are looking for a PhD in genome stability and cancer therapeutics get in touch and apply ! https://lnkd.in/etTW7fAA
-
Barts Cancer Institute (Queen Mary University of London) reposted this
🚨 PhD Opportunity in Cancer Research: B Cell Dynamics and ECM Topography in Melanoma 🚨 Are you passionate about applying your expertise in deep learning and computer vision to cancer research? Join our team to explore the spatial relationships between the extracellular matrix (ECM) and B cell plasticity during melanoma progression. Together, we will uncover new biomarkers for risk prediction and improve our understanding of tumour dynamics! This fully funded PhD position at Barts Cancer Institute (Queen Mary University of London), Queen Mary University of London, as part of the Cancer Research UK City of London Centre, focuses on "Understanding B Cell Dynamics and ECM Topography in Melanoma Through Multiomic Analysis and Predictive Modelling of Risk Signatures." The project is co-supervised by Dr. Oscar Maiques (QMUL) and Prof Sophia N Karagiannis King's College London. 💡 What you’ll do: Apply deep learning and computer vision techniques to uncover the role of B cells in melanoma progression Use cutting-edge imaging modalities and multiomic approaches, including spatial transcriptomics Develop predictive models for B cell activity and melanoma risk Investigate ECM remodelling and B cell infiltration as key markers of disease progression 🧠 Candidate Requirements: Master’s degree in bioinformatics, machine learning, or a related field Experience in advanced imaging, RNA-seq, and spatial transcriptomics (desired) Proficiency in Python or R Strong analytical skills and knowledge in cancer biology or immunology (recommended) 🗓 Application Deadline: 5th November 2024 🔗 Project Details (Project 6) https://lnkd.in/eMR_ZJCi 🔗 Application Link https://lnkd.in/eJvBhz-F This position covers tuition fees for Home status applicants (see eligibility criteria). Feel free to share or tag someone who may be interested! #PhD #CancerResearch #DeepLearning #ComputerVision #SpatialTranscriptomics #Bioinformatics #Melanoma #BartsCancerInstitute #KingsCollegeLondon #QMUL #CRUKCityOfLondon
2025 PhD project Maiques
https://www.colcc.ac.uk
-
Barts Cancer Institute (Queen Mary University of London) reposted this
🎉 The theme for our Annual Symposium 2025 is... early career researchers! 💥 Our call for abstracts is now OPEN and we're looking for exciting talks/posters across our research themes of novel biological therapies, effective therapeutical combinations, cancer evolution, prevention and early detection, and paediatrics. 👨👩👧👦 Members of the RadNet radiation research network and experts in public and patient involvement and engagement are also warmly invited to present. 🏃♀️ This opportunity is exclusive to members of our Centre. Submit your abstract by Friday 11 October: https://lnkd.in/edyc5mE5 The symposium will take place on 27-28th January in London. The Francis Crick Institute | UCL Cancer Institute | King's Faculty of Life Sciences & Medicine | Barts Cancer Institute (Queen Mary University of London)
-
Barts Cancer Institute (Queen Mary University of London) reposted this
In October this year, we will be marking Black History Month, an opportunity to celebrate the achievements, contributions and histories of Black people in the UK and around the world. Black History Month is an annual celebration highlighting the contributions, successes, and achievements of the Black community. This year, the national theme is 'Reclaiming Narratives’. At Queen Mary we will be celebrating Black History Month 2024 with a programme of virtual events, initiatives and communications from 1 - 31 October. Queen Mary University of London seeks to be the most inclusive university of our kind, anywhere, by 2030. We are proud to be a university that opens the doors of opportunity to anyone with the potential to succeed. We are also proud to celebrate how diverse our communities are, with over 170 nationalities and 75% of our undergraduate students coming from a Black, Asian, and Minority Ethnic background. Read more: https://lnkd.in/evvg66_3
-
This #BloodCancerAwarenessMonth we spoke to Dr Lou Herman about her work exploring differences in blood cancer between men and women. 📰 Read more: https://lnkd.in/e3VuJQq9 One of the biggest challenges with blood cancer is that every single patient is different, with different genetics, different immune systems and different responses to treatments. This includes differences between men and women. Why blood cancer affects men and women differently is poorly understood – if we can understand where these differences exist, we can assess their impact on treatments, ultimately providing treatments and dosing with maximum efficacy and minimal toxicity for both men and women. 💬 Professor John Gribben, who leads our Centre for Haemato-Oncology says: "Lou’s novel approach to her work is already making inroads into understanding how males and females respond differently to treatment and this will surely open up new avenues to address how we increase the safety and efficacy of our treatments for blood cancer." #bloodcancer #cancerresearch Queen Mary University of London | Queen Mary Faculty of Medicine and Dentistry | Cancer Research UK City of London Centre